EVOTEC SE

Evotec partners with Odyssey Therapeutics to accelerate AI‑driven drug discovery for autoimmune and inflammatory diseases, boosting pipeline and investor confidence.

Discover how Evotec SE drives drug discovery across neuroscience, oncology, diabetes and more, leveraging cutting‑edge tech to tackle unmet medical needs.

Short‑selling data shows investor doubt in Evotec SE—negative PE, near 52‑week lows, yet broader German indices rise. Explore why traders are betting on a dip.

Evotec SE stock dips to €5.31 amid selling pressure, yet potential Tubulis partnership and bullish RBC target hint at a rebound; read the latest market analysis.

Evotec SE surges in the German tech‑sector, climbing TecDAX with analyst‑backed buy ratings, a €10 target, and a robust neuroscience‑oncology pipeline. Click for the full investment insight.

Evotec SE’s Sandoz deal and Novo Holdings exit show how fragile investor confidence can be, and why AI‑driven R&D may be the key to long‑term growth.

Evotec SE’s shares tumble after Novo Nordisk Fonden exits and board insiders trade, revealing how institutional shifts and insider moves shape investor sentiment in the life‑science market.

Evotec SE discloses voting‑rights filings, CEO’s marathon restructuring remarks, JPMorgan stake cut, and shares hit a 52‑week high—an in‑depth look at the company’s governance and market impact.

Evotec SE, a German life sciences services provider, is navigating a new era of AI-driven drug discovery amidst market volatility, with its share price influenced by regulatory scrutiny of short-selling practices and the potential for undervaluation…

Evotec SE and Sandoz AG have announced a non-binding agreement for the potential sale of Evotec’s Toulouse biologics facility to Sandoz for approximately $300 million.